Amgen Hopes For Broad T-VEC Label, But Is Prepared To Discuss Narrower Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech reported a strong financial quarter while updating on several R&D and business catalysts, including the potential indications for its PCSK9 inhibitor.